22 Results for "

Human hematological malignancies

" in MedChemExpress (MCE) Product Catalog:
Products (22)

22 Results for "Human hematological malignancies" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-129179
CAS No.: 2180923-05-9
Purity:  99.28%
Synonyms: APG-2575; Bcl-2/Bcl-xl inhibitor 1
Target:  

Bcl-2 Family Apoptosis

Research Areas:  

Cancer

Lisaftoclax is an orally active, selective BCL-2 inhibitor with a Ki of < 0.1 nM against human BCL-2. Lisaftoclax selectively binds to BCL-2, disrupts the BCL-2:BIM complex, and antagonizes the antiapoptotic function of BCL-2. Lisaftoclax induces BAX/BAK-dependent, caspase-mediated apoptosis, upregulates the pro-death proteins BIM and Noxa, and downregulates mitochondrial respiratory function and ATP production. Lisaftoclax can be used in the research of hematological malignancies including chronic lymphocytic leukemia, multiple myeloma, and diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-150105
CAS No.: 2448172-22-1
Purity:  98.72%
Synonyms: BMF-219; Menin-MLL inhibitor 21
Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes .
loading...
    loading...
Cat. No.: HY-P990033
CAS No.: 2543693-10-1
Synonyms: CC-95251; BMS-986351

Target:  

CD47

Research Areas:  

Cancer

Anzurstobart (CC-95251; BMS-986351) is a CD47/SIRPα inhibitor with human SIRPα Kd of 0.0541 nM and human SIRPα IC50 of 100 nM. Anzurstobart binds SIRPα at a CD47-overlapping site, blocks CD47-SIRPα interactions, inhibits CD47-SIRPα axis signaling, and binds across 6 prevalent human SIRPα haplotypes. Anzurstobart binds SIRPγ and inhibits CD47-SIRPγ interactions. Anzurstobart can be used for the research of non-Hodgkin's lymphoma, colorectal cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, and advanced solid and hematologic malignancies .
loading...
    loading...
Cat. No.: HY-16496
CAS No.: 26599-17-7
Synonyms: OSI-7836
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

Thiarabine (OSI-7836) is an orally active cytotoxic antitumor agent that acts as a deoxycytidine kinase substrate and a DNA chain terminator. Thiarabine is metabolized to form its major active metabolite T-araCTP, which potently inhibits DNA synthesis and exhibits a long retention time in tumor cells. Thiarabine is widely applicable to research related to leukemia, lymphoma, hematologic malignancies, acute myeloid leukemia, and advanced solid malignancies .
loading...
    loading...
Cat. No.: HY-P11097
CAS No.: 3056822-31-9
Target:  

CD47

Research Areas:  

Cardiovascular Disease Cancer

Pep-20 is a CD47 binder with a human Kd of 2.91 µM and a murine Kd of 3.63 µM. Pep-20 blocks the interaction between CD47 and SIRPα, with an IC50 of 24.56 µM for human targets and 12.03 µM for murine targets. Pep-20 also acts as a phagocytosis enhancer and an inducer of anti-tumor immune responses. By blocking the CD47/SIRPα interaction, Pep-20 reduces the tyrosine phosphorylation level of SIRPα, disrupts the inhibitory "don't eat me" signaling pathway, enhances macrophage-mediated phagocytosis of solid tumor cells and hematologic tumor cells, and promotes macrophage mobilization of anti-tumor T-cell responses. Pep-20 can be used in research related to solid tumors, hematologic malignancies, breast cancer, and pancreatic cancer .
loading...
    loading...
Cat. No.: HY-P991656
CAS No.: 2125546-89-4

Target:  

CXCR Apoptosis p38 MAPK Akt

Research Areas:  

Cancer

LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting CXCR4. LY-2624587 blocks SDF-1/CXCR4 interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research .
loading...
    loading...
Cat. No.: HY-P991135
CAS No.: 2999644-88-9
Synonyms: RO-7502175; RG-6411

Target:  

CCR

Research Areas:  

Cancer

Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .
loading...
    loading...
Cat. No.: HY-P991151
CAS No.: 2923499-76-5
Synonyms: LBL-024

Target:  

PD-1/PD-L1 TNF Receptor

Research Areas:  

Cancer

Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .
loading...
    loading...
Cat. No.: HY-E70842
Target:  

MEK

Research Areas:  

Cancer

MAP2K1 (also known as MEK1) is downstream of the RAF family and activation results in ERK1/2 activation. Activating mutations in MAP2K1 have been reported almost exclusively in exons 1 and 2 in both hematologic malignancies. MAP2K1 L115P is a mutant of MAP2K1. MAP2K1 L115P Recombinant Human Active Protein Kinase is a recombinant MAP2K1 L115P protein that can be used to study MAP2K1 L115P-related functions .
loading...
    loading...
Cat. No.: HY-P5472
CAS No.: 129437-45-2
Research Areas:  

Others

Tumour-associated MUC1 epitope is a biological active peptide. (This sequence is the hallmark of MUC1 mucin. MUC1 is a highly glycosylated type I transmembrane glycoprotein with a unique extracellular domain consisting of a variable number of tandem repeats (VNTR) of this 20 amino acid peptide. It is overexpressed on the cell surface of many human adenocarcinomas and hematological malignancies, including multiple myeloma and B-cell lymphoma, making MUC1 broadly applicable target for immunotherapeutic strategies.)
loading...
    loading...
Cat. No.: HY-P990954
CAS No.: 2850355-94-9
Synonyms: IMM-0306

Target:  

CD47 CD20

Research Areas:  

Cancer

Amulirafusp alfa (IMM-0306) is a fusion protein of CD20 monoclonal antibody (mAb) with the CD47 binding domain of SIRPα, with human CD20 Kd 2.45 nM and human CD47 Kd 4.91 nM. Amulirafusp alfa binds to CD20 and CD47 on B cells, engages FcɣR, blocks CD47-SIRPα interaction, activates macrophages, NK cells, and complement cascade, mediates phagocytosis and cytotoxicity, inhibits apoptosis of Jurkat-CSR cells, reverses IL-16 tumor-promoting effects, and binds human/cynomolgus CD47 but not mouse/rat CD47. Amulirafusp alfa can be used for the research of hematological malignancies, relapsed or refractory CD20-positive B-cell non-Hodgkin’s lymphoma, relapsed or refractory B-cell non-Hodgkin lymphoma, and activated B-cell-like diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-108864
CAS No.: 113427-24-0
Synonyms: Epogen

Research Areas:  

Cardiovascular Disease Cancer

Epoetin alfa (Epogen) is a recombinant human erythropoietin whose amino acid sequence and biological activity are identical to those of endogenous erythropoietin (EPO). Epoetin alfa is a direct agonist of the EPO receptor (EPOR) on the surface of erythroid progenitor cells, and promotes the production and maturation of red blood cells. Epoetin alfa can be used for research on myelodysplastic syndrome-related anemia and hematological malignancies .
loading...
    loading...
Cat. No.: HY-P992439

Target:  

CXCR

Research Areas:  

Cancer

PF-06747143 is recombinant anti-human antibody targeting CXCR4. PF-06747143 blocks CXCL12-induced calcium flux, F-actin polymerization, chemotaxis, cell migration, and leukemic cell bone marrow homing. PF-06747143 reduces tumor burden and improves survival in mouse models of hematologic malignancies. PF-06747143 can be used for the research of chronic lymphocytic leukemia, acute myeloid leukemia, and hematologic malignancies .
loading...
    loading...
Cat. No.: HY-181086
CAS No.: 2864394-30-7
Research Areas:  

Cancer

FLT3/HDAC-IN-3 is a dual inhibitor of FLT3 and HDAC. FLT3/HDAC-IN-3 potently inhibits FLT3 (IC50 = 14 nM), HDAC1 (IC50 = 27 nM), HDAC6 (IC50 = 20 nM), and FLT3 D853Y (IC50 = 55 nM), exhibits weak activity against HDAC8, and shows no activity against HDAC4. FLT3/HDAC-IN-3 possesses kinase selectivity, plasma stability, and stability in human liver microsomes. FLT3/HDAC-IN-3 demonstrates anti-proliferative effects in a variety of hematological malignancy cell lines. FLT3/HDAC-IN-3 shows efficacy in the Jeko-1 xenograft model without observed significant toxicity. FLT3/HDAC-IN-3 can be used in the study of hematological malignancies .
loading...
    loading...
Cat. No.: HY-182700
CAS No.: 717863-53-1
Target:  

Complement System VEGFR

Research Areas:  

Cancer

NRPa-308 is a potent and orally active Neuropilin-1 (NRP-1) antagonist with an IC50 of 42 μM for inhibiting VEGF-A165 binding to NRP-1. NRPa-308 blocks the specific interaction between VEGF-A165 and NRP-1. NRPa-308 effectively suppresses angiogenesis in vitro and in vivo and reduces the viability of a broad spectrum of human solid and haematological cancer cells. NRPa-308 inhibits tumor growth and prolongs median survival in a human breast cancer xenograft mouse model. NRPa-308 can be used for the research of multiple human malignancies including solid tumors and hematological cancers .
loading...
    loading...
Cat. No.: HY-187360
CAS No.: 3087291-81-1
Research Areas:  

Others

MC-Val-Ala-PAB-NH-Ph-CO-piperidin-4-ol-C4-NH-cyanoguanidine is a cathepsin B-cleavable linker-payload, with Nampt-IN-22 (HY-187336) as its toxin moiety. MC-Val-Ala-PAB-NH-Ph-CO-piperidin-4-ol-C4-NH-cyanoguanidine can be used for the synthesis of ADC .
loading...
    loading...
Cat. No.: HY-184230
CAS No.: 3120899-50-2
Research Areas:  

Cancer

PROTAC HPK1 Degrader-8 is a HPK1 PROTAC degrader with a DC50 of 1-10 nM. PROTAC HPK1 Degrader-8 promotes HPK1 ubiquitination and degradation. PROTAC HPK1 Degrader-8 induces IL-2 production, with an EC50 of 3 nM. PROTAC HPK1 Degrader-8 can be used in research related to hematologic malignancies and solid tumors .
loading...
    loading...
Cat. No.: HY-184823
CAS No.: 1417634-25-3
Target:  

Casein Kinase

Research Areas:  

Cancer

CK2-IN-17 is a protein kinase CK2 inhibitor with an IC50 of 9.5 μM against human targets. CK2-IN-17 regulates the activity of protein kinase CK2 by interacting with its ATP-binding site. CK2-IN-17 can be used in studies related to protein kinase CK2-mediated pathways, such as tumors .
loading...
    loading...
loading...
    loading...
Cat. No.: HY-16496A
CAS No.: 1060763-87-2
Synonyms: OSI-7836 hydrochloride
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

Thiarabine (OSI-7836) hydrochloride is an orally active cytotoxic antitumor agent that acts as a deoxycytidine kinase substrate and a DNA chain terminator. Thiarabine hydrochloride is metabolized to form its major active metabolite T-araCTP, which potently inhibits DNA synthesis and exhibits a long retention time in tumor cells. Thiarabine hydrochloride is widely applicable to research related to leukemia, lymphoma, hematologic malignancies, acute myeloid leukemia, and advanced solid malignancies .
loading...
    loading...